Nanobiotix to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Nanobiotix (Euronext: NANO – NASDAQ: NBTX), a private biotechnology company recognized for its innovative physics-driven cancer therapies, is preparing to take part in a special fireside chat at the upcoming H.C. Wainwright 26th Annual Global Investment Conference.
Event Information
This important event is set for Wednesday, September 11, 2024. The discussion will begin at 9:30 AM EDT (3:30 PM CEST) and will be live-streamed, allowing interested stakeholders, investors, and other relevant parties to tune in.
Featured Speakers
Attendees will gain insights from key leaders at Nanobiotix, including Laurent Levy, the co-founder and chairman of the executive board, alongside Bart Van Rhijn, the company's chief financial officer. This session is expected to explore the groundbreaking research and advancements that reflect Nanobiotix's dedication to enhancing cancer treatment.
About Nanobiotix
Founded in 2003 and based in Paris, Nanobiotix has established itself as a notable player in the biotechnology field, focusing on improving treatment strategies for cancer patients. The company is committed to pushing the limits of scientific knowledge to develop innovative healthcare solutions.
Company Achievements
Having been listed on Euronext since 2012 and on the Nasdaq Global Select Market since December 2020, Nanobiotix has consistently progressed and built a strong presence in various regions, including Cambridge, Massachusetts, where it plays a crucial role in the biotech industry.
Innovative Therapeutic Platforms
The company holds over 25 patent families and has created three groundbreaking nanotechnology platforms that focus on oncology, enhancing drug bioavailability, and addressing central nervous system disorders. This diverse approach enables Nanobiotix to make significant advancements in therapeutic innovation.
Final Thoughts
As Nanobiotix prepares for its participation in the H.C. Wainwright conference, excitement grows regarding its potential to transform treatment approaches in oncology. Both industry experts and investors are keen to discover more about the company's advancements and their impact on cancer care.
Frequently Asked Questions
1. What is the main focus of Nanobiotix in cancer treatment?
Nanobiotix aims to revolutionize cancer treatment through physics-based therapeutic approaches, improving outcomes for patients.
2. Who will be speaking at the conference?
The conference features Laurent Levy and Bart Van Rhijn from Nanobiotix, who will share insights into the company's innovations.
3. When is the Nanobiotix presentation at the H.C. Wainwright conference?
The presentation is scheduled for September 11, 2024, at 9:30 AM EDT.
4. How can investors listen to the fireside chat?
The session will be streamed live on the Investors section of Nanobiotix's official website.
5. What is unique about Nanobiotix's therapeutic approaches?
Nanobiotix is known for its disruptive, physics-based therapies that aim to push beyond traditional treatment boundaries in oncology.
